Phase I evaluation of lenvatinib and weekly paclitaxel in patients with recurrent endometrial, ovarian, fallopian tube, or primary peritoneal Cancer
Authors:
- 1 September 2021
- journal article
- research article
- Published by Elsevier in Gynecologic Oncology
- Vol. 162 (3) , 619-625
Abstract
No abstract availableKeywords
Funding Information
- Eisai Korea Inc
This publication has 25 references indexed in Scilit:
- Bevacizumab Combined With Chemotherapy for Platinum-Resistant Recurrent Ovarian Cancer: The AURELIA Open-Label Randomized Phase III TrialJournal of Clinical Oncology, 2014
- Phase II Trial of Bevacizumab in Recurrent or Persistent Endometrial Cancer: A Gynecologic Oncology Group StudyJournal of Clinical Oncology, 2011
- Addition of bevacizumab to weekly paclitaxel significantly improves progression-free survival in heavily pretreated recurrent epithelial ovarian cancerGynecologic Oncology, 2011
- Emerging therapeutic targets in endometrial cancerNature Reviews Clinical Oncology, 2011
- Multi-Kinase Inhibitor E7080 Suppresses Lymph Node and Lung Metastases of Human Mammary Breast Tumor MDA-MB-231 via Inhibition of Vascular Endothelial Growth Factor-Receptor (VEGF-R) 2 and VEGF-R3 KinaseClinical Cancer Research, 2008
- A phase II trial of weekly 1-hour paclitaxel as second-line therapy for endometrial and cervical cancerInternational Journal of Clinical Oncology, 2008
- E7080, a novel inhibitor that targets multiple kinases, has potent antitumor activities against stem cell factor producing human small cell lung cancer H146, based on angiogenesis inhibitionInternational Journal of Cancer, 2007
- Bevacizumab and weekly taxane chemotherapy demonstrates activity in refractory ovarian cancerGynecologic Oncology, 2006
- Phase II trial of weekly paclitaxel (80 mg/m2) in platinum and paclitaxel-resistant ovarian and primary peritoneal cancers: A Gynecologic Oncology Group studyGynecologic Oncology, 2006
- Clinical Pharmacokinetics of PaclitaxelClinical Pharmacokinetics, 1994